Rhupus综合征的临床特点

doi:10.19723/j.issn.1671-167X.2021.05.020

Abstract

Abstract:

Objective: To investigate the clinical and serological features of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) overlap syndrome (Rhupus syndrome). Methods: We retrospectively reviewed the medical records of 21 patients with Rhupus syndrome who were hospitalized at Department of Rheumatology and Immunology, People’s Hospital of Xinjiang Uygur Autonomous Region between January 2010 and January 2018. We compared the joint involvement, autoantibodies and clinical manifestations of Rhupus syndrome with 81 cases of RA-alone and 51 cases of SLE-alone. Results: In 21 patients with Rhupus syndrome, there are 3 males and 18 females. Compared with the SLE-alone group, the patients with Rhupus syndrome were older [(49.43±11.66) vs. (40.59±12.73), P=0.008]. The median age of the patients with Rhupus syndrome at RA onset was significantly younger than that of the RA-alone patients [(32.58±11.14) vs. (43.11±11.83), P=0.010]. Of the 21 patients with Rhupus syndrome, the initial diagnosis was RA in 57% (12/21), except 2 male patients, the other 10 patients with SLE manifestations were menopause, the mean age of amenorrhea or menopause was (44.30±5.33) (36-50) years. The mean interval between the onset of SLE and RA was 10.83 years. Two patients started with SLE manifestations. Moreover, both diseases simultaneously developed in 33.3% of the patients. Except one male patient, 3 patients were in menopause stage when RA and SLE appeared. The positive rate of specific antibody Rhupus syndrome was similar to that of RA. Renal damage was relatively rare in SLE related manifestations, but the incidence of interstitial lung disease was higher. There were no significant differences in the prevalence of complements C3 and C4, antinuclear antibody (ANA), anti-double-stranded DNA (anti-dsDNA), anti-SSA or anti-SSB antibody between the Rhupus syndrome and SLE-alone group. Conclusion: Rhupus syndrome is an overlapping syndrome in which RA and SLE coexist. Most of the diseases occur in RA and the related manifestations of RA are more serious than those of SLE. The incidence of Rhupus syndrome may be related to the change of sex hormone levels.

Key words: Arthritis, rheumatoid, Lupus Erythematosus, systemic, Rhupus syndrome

CLC Number:

R593.2

Zheng-fang LI,Xue WU,Li-jun WU,Cai-nan LUO,Ya-mei SHI,Yan ZHONG,Xiao-mei CHEN,Xin-yan MENG. Clinical features of patients with Rhupus syndrome[J].Journal of Peking University (Health Sciences), 2021, 53(5): 933-937.

Figures/Tables 3

Table 1

Demographic characteristics of three groups of patients"

Items	Rhupus syndrome (n=21)	RA-alone (n=81)	SLE-alone (n=51)
Age/years, $x ?$ ±s	49.43±11.66	52.21±10.96	40.59±12.73^*
Female/%	85.7	84.0	96.1
Age at SLE onset/years, $x ?$ ±s	25.56±6.36		33.71±12.94
Age at RA onset/years, $x ?$ ±s	32.58±11.14	43.11±11.83^*
Duration of SLE/years, $x ?$ ±s	4.00±1.41		6.92±6.15
Duration of RA/years, $x ?$ ±s	10.83±8.44	8.94±7.47

Table 1

Table 2

Table 3

References 19

[1]	Amezcua-Guerra LM, Springall R, Marquez-Velasco R, et al. Presence of antibodies against cyclic citrullinated peptides in patients with “Rhupus”: A cross-sectional study [J]. Arthritis Res Ther, 2006, 8(5):R144. doi: 10.1186/ar2036
[2]	Toone EC Jr, Irby R, Pierce EL. The L.E. cell in rheumatoid arthritis [J]. Am J Med Sci, 1960, 240(5):599-608.
[3]	Schur PH. Systemic lupus erythematosus [M]//Beeson PB, McDermott W. Cecil-loeb textbook of medicine. 13th ed. Philadelphia, PA: WB Saunders, 1971: 821.
[4]	Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis [J]. Arthritis Rheum, 1988, 31(3):315-324. doi: 10.1002/(ISSN)1529-0131
[5]	Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J]. Arthritis Rheum, 1997, 40(9):1725.
[6]	Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited [J]. J Am Soc Nephrol, 2004, 15(2):241-250. pmid: 14747370
[7]	穆荣, 叶华, 陈适, 等. Rhupus综合征的回顾性临床分析 [J]. 中华内科杂志, 2006, 45(7):540-543.
[8]	Hayakawa S, Komine-Aizawa S, Osaka S, et al. Rembrandt’s Maria Bockenolle has a butterfly rash and digital deformities: Overlapping syndrome of rheumatoid arthritis and systemic lupus erythematosus [J]. Med Hypotheses, 2007, 68(4):906-909. pmid: 17113236
[9]	Fernandez A, Quintana G, Matteson EL, et al. Lupus arthropathy: Historical evolution from deforming arthritis to rhupus [J]. Clin Rheumatol, 2004, 23(6):523-526. doi: 10.1007/s10067-004-0951-2
[10]	Simon JA, Granados J, Cabiedes J, et al. Clinical and immunogenetic characterization of Mexican patients with “Rhupus” [J]. Lupus, 2002, 11(5):287-292. doi: 10.1191/0961203302lu189oa
[11]	Tani C, D’Aniello D, Sedie AD, et al. Rhupus syndrome: Assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients [J]. Autoimmun Rev, 2013, 12(4):537-541. doi: 10.1016/j.autrev.2012.09.004 pmid: 23063507
[12]	Liu T, Li G, Mu R, et al. Clinical and laboratory profiles of rhupus syndrome in a Chinese population: A single-centre study of 51 patients [J]. Lupus, 2014, 23(9):958-963. doi: 10.1177/0961203314526439 pmid: 24608963
[13]	Li J, Wu H, Huang X, et al. Clinical analysis of 56 patients with rhupus syndrome: Manifestations and comparisons with systemic lupus erythematosus: A retrospective case-control study [J]. Me-dicine, 2014, 93(10):e49.
[14]	Ceccarelli F, Perricone C, Cipriano E, et al. Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessment [J]. Semin Arthritis Rheum, 2017, 47(1):53-64. doi: 10.1016/j.semarthrit.2017.03.022
[15]	Sundaramurthy SA, Karsevar MP, van Vollenhoven RV. Influence of hormonal events on disease expression in patients with the combination of systemic lupus erythematosus and rheumatoid arthritis [J]. J Clin Rheumatol, 1999, 5(1):9-16. pmid: 19078342
[16]	Piga M, Gabba A, Cauli A, et al. Rituximab treatment for “rhupus syndrome”: Clinical and power-Doppler ultrasonographic monitoring of response. A longitudinal pilot study [J]. Lupus, 2013, 22(6):624-628. doi: 10.1177/0961203313482741 pmid: 23559669
[17]	Ikeda K, Sanayama Y, Makita S, et al. Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus [J]. Clin Dev Immunol, 2013, 2013:697525.
[18]	Iaccarino L, Gatto M, Bettio S, et al. Overlap connective tissue disease syndromes [J]. Autoimmun Rev, 2013, 12(3):363-373. doi: 10.1016/j.autrev.2012.06.004 pmid: 22743033
[19]	Danion F, Sparsa L, Arnaud L, et al. Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: An open-label study of 15 patients [J]. RMD Open, 2017, 3(2):e000555. doi: 10.1136/rmdopen-2017-000555

Related Articles 15

[1]	Zhihui WU, Mingzhi HU, Qiaoying ZHAO, Fengfeng LV, Jingying ZHANG, Wei ZHANG, Yongfu WANG, Xiaolin SUN, Hui WANG. Immunomodulatory mechanism of umbilical cord mesenchymal stem cells modified by miR-125b-5p in systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 860-867.
[2]	Dongwu LIU, Jie CHEN, Mingli GAO, Jing YU. Rheumatoid arthritis with Castleman-like histopathology in lymph nodes: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 928-931.
[3]	Zhengfang LI,Cainan LUO,Lijun WU,Xue WU,Xinyan MENG,Xiaomei CHEN,Yamei SHI,Yan ZHONG. Application value of anti-carbamylated protein antibody in the diagnosis of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 729-734.
[4]	Huina HUANG,Jing ZHAO,Xiangge ZHAO,Ziran BAI,Xia LI,Guan WANG. Regulatory effect of lactate on peripheral blood CD4⁺ T cell subsets in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 519-525.
[5]	Limin REN,Chuchu ZHAO,Yi ZHAO,Huiqiong ZHOU,Liyun ZHANG,Youlian WANG,Lingxun SHEN,Wenqiang FAN,Yang LI,Xiaomei LI,Jibo WANG,Yongjing CHENG,Jiajing PENG,Xiaozhen ZHAO,Miao SHAO,Ru Li. Low disease activity and remission status of systemic lupus erythematosus in a real-world study [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 273-278.
[6]	Xiaofei TANG,Yonghong LI,Qiuling DING,Zhuo SUN,Yang ZHANG,Yumei WANG,Meiyi TIAN,Jian LIU. Incidence and risk factors of deep vein thrombosis in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 279-283.
[7]	Hongguang LI,Weihua HAN,Xun WU,Jiling FENG,Gang LI,Juanhong MENG. Preliminarily study of arthrocentesis combined with liquid phase concentrated growth factor injection in the treatment of unilateral temporomandibular joint osteoarthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 338-344.
[8]	Xue ZOU,Xiao-juan BAI,Li-qing ZHANG. Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1013-1021.
[9]	Wen-gen LI,Xiao-dong GU,Rui-qiang WENG,Su-dong LIU,Chao CHEN. Expression and clinical significance of plasma exosomal miR-34-5p and miR-142-3p in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1022-1027.
[10]	Zhi-jun LUO,Jia-jia WU,You SONG,Chun-li MEI,Rong DU. Systemic lupus erythematosus associated macrophage activation syndrome with neuropsychiatric symptoms: A report of 2 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1111-1117.
[11]	Hai-hong YAO,Fan YANG,Su-mei TANG,Xia ZHANG,Jing HE,Yuan JIA. Clinical characteristics and diagnostic indicators of macrophage activation syndrome in patients with systemic lupus erythematosus and adult-onset Still's disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 966-974.
[12]	Xiang-ge ZHAO,Jia-qing LIU,Hui-na HUANG,Zhi-min LU,Zi-ran BAI,Xia LI,Jing-jing QI. Interferon-α mediating the functional damage of CD56^dimCD57⁺natural killer cells in peripheral blood of systemic lupus erythematosuss [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 975-981.
[13]	Qi WU,Yue-ming CAI,Juan HE,Wen-di HUANG,Qing-wen WANG. Correlation between dyslipidemia and rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 982-992.
[14]	Jing-feng ZHANG,Yin-ji JIN,Hui WEI,Zhong-qiang YAO,Jin-xia ZHAO. Correlation analysis between body mass index and clinical characteristics of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 993-999.
[15]	Yin-ji JIN,Lin SUN,Jin-xia ZHAO,Xiang-yuan LIU. Significance of IgA isotype of anti-v-raf murine sarcoma viral oncogene homologue B1 antibody in rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 631-635.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 0

No Suggested Reading articles found!

Items	Rhupus syndrome (n=21)	RA-alone (n=81)
Clinical features, n(%)
Morning stiffness	18 (85.7)	56 (69.1)
Polyarthritis	20 (95.2)	77 (95.1)
Rheumatoid nodule	1 (4.7)	8 (9.9)
Laboratory features, n(%)
RF	19 (90.5)	68 (84.0)
Anti-CCP	14 (66.7)	75 (92.6)^*
AKA	7 (33.3)	27 (33.3)
APF	8 (38.1)	11 (13.6)^*
Erosions on radiography, n(%)	20 (95.2)	65 (80.2)

Items	Rhupus syndrome (n=21)	SLE-alone (n=51)
Clinical features, n(%)
Malar or discoid lupus	5 (23.8)	28 (54.9)^*
Oral ulcers	3 (14.2)	11 (21.6)
Raynaud’s phenomena	5 (23.8)	8 (15.6)
Renal disorder (proteinuria)	5 (23.8)	26 (50.9)^*
Interstitial pulmonary diseases	10 (47.6)	5 (9.8)^△
Haematological disorder	12 (57.1)	25 (49.0)
Laboratory features, n(%)
ESR	21 (100.0)	39 (76.4)^*
CRP	16 (76.2)	20 (39.2)^#
Decreased complement C3	16 (76.2)	37 (72.5)
Decreased complement C4	16 (76.2)	43 (84.3)
Anti-dsDNA	9 (42.8)	34 (66.7)
SSA	12 (57.1)	34 (66.7)
SSB	2 (9.5)	11 (21.6)
RF	19 (90.5)	8 (15.6)^△
Anti-CCP	14 (66.7)	0^△

Clinical features of patients with Rhupus syndrome

RICH HTML

PDF (PC)